REDWOOD CITY, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- California based myoscience, inc., makers of the revolutionary iovera° system for treatment of peripheral nerves, has been named a winner of the prestigious Red Herring 2014 Top 100 North America Award. As a winner, myoscience joins a short list that honors the year's most promising private companies. Starting from a field of over 3,000 candidates, myoscience was selected as a Top 100 winner by Red Herring.
Award winners were selected using a rigorous evaluation process that included both quantitative and qualitative criteria, such as financial performance, technological innovation and intellectual property, management quality, business model, customer footprint and market penetration.
Myoscience's groundbreaking iovera° treatment utilizes the body's natural response to cold to deliver immediate results for both therapeutic and aesthetic applications. The iovera° system is FDA cleared for the treatment of pain in the United States and is approved in the European Union and Canada for the treatment of wrinkles.
"In 2014, selecting the top 100 achievers was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from all the candidates across North America to the top 100 winners. We believe myoscience embodies the vision, drive and innovation that define a successful entrepreneurial venture. Myoscience should be proud of its accomplishment, as the competition was very strong."
"We are proud of our team, grateful to our investors, and very honored to have been selected for this highly coveted distinction," said myoscience CEO Clint Carnell. "This selection further validates the hard-work and dedication of our team in bringing this remarkable platform technology to patients around the world."
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0250 REV A